FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4249331300> ?p ?o ?g. }

• W4249331300 endingPage "5153" @default.
• W4249331300 startingPage "5153" @default.
• W4249331300 abstract "5153 Background: Topotecan is an active second-line agent for ovarian cancer but combinations with carboplatin have been limited by myeolsuppression. Weekly topotecan has been associated with less myelosuppression and moderate activity. We performed a phase I trial of weekly topotecan and carboplatin in potentially platinum sensitive ovarian and peritoneal carcinoma. Methods: Patients with evaluable potentially platinum sensitive ovarian or peritoneal carcinoma with PS 0–2, normal bone marrow, renal and hepatic function were eligible. Patients with a creatinine clearance of <50 cc/min by Jelliffe were excluded. Carboplatin at an AUC of 4 and in subsequent patients at an AUC of 5 with topotecan 2.0 mg/m2 was administered IV on day 1 each over 30 minutes. Topotecan at 2.0 mg/m2 was administered on days 8 and 15 provided the day of therapy ANC was ≥1,500/mcl and platelet count ≥100,000/mcl. Cycles were prescribed every 21 days. Dose escalation of topotecan was planned at 0.5 mg/m2 increments to a maximum of 4 mg/m2/week. Results: Thirteen patients were enrolled with 64 (median 5) every 21 day courses have been administered. With carboplatin at an AUC of 4, dose limiting toxicity was seen with topotecan at the starting dose of 2.0 mg/m2 and further escalation of topotecan was not possible. Since the dose limiting toxicity was neutropenia, the dose of carboplatin was elevated to an AUC of 5. This was tolerated with topotecan on day 1 and 8, but the day 15 dose was held on 43/64 (85%) of treatments due to inadequate neutrophil and/or platelet counts. Weekly topotecan on day 1 and 8 was well tolerated but in all but one patient, when day 15 topotecan was administered delays in subsequent therapy occurred. Responses have been seen in 7 of 10 evaluable patients. Conclusion: Carboplatin at an AUC of 5 in combination with topotecan at a dose of 2.0 mg/m2 on day 1and 8 is tolerable and active in potentially platinum sensitive ovarian or peritoneal carcinoma. A phase II study is planned. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline GlaxoSmithKline" @default.
• W4249331300 created "2022-05-12" @default.
• W4249331300 creator A5005911289 @default.
• W4249331300 creator A5017242750 @default.
• W4249331300 creator A5040955968 @default.
• W4249331300 creator A5043720889 @default.
• W4249331300 creator A5049897942 @default.
• W4249331300 date "2004-07-15" @default.
• W4249331300 modified "2023-09-25" @default.
• W4249331300 title "A phase I trial of weekly topotecan and carboplatin in potentially platinum sensitive ovarian and peritoneal carcinoma" @default.
• W4249331300 doi "https://doi.org/10.1200/jco.2004.22.90140.5153" @default.
• W4249331300 hasPublicationYear "2004" @default.
• W4249331300 type Work @default.
• W4249331300 citedByCount "0" @default.
• W4249331300 crossrefType "journal-article" @default.
• W4249331300 hasAuthorship W4249331300A5005911289 @default.
• W4249331300 hasAuthorship W4249331300A5017242750 @default.
• W4249331300 hasAuthorship W4249331300A5040955968 @default.
• W4249331300 hasAuthorship W4249331300A5043720889 @default.
• W4249331300 hasAuthorship W4249331300A5049897942 @default.
• W4249331300 hasConcept C112705442 @default.
• W4249331300 hasConcept C121608353 @default.
• W4249331300 hasConcept C126322002 @default.
• W4249331300 hasConcept C126894567 @default.
• W4249331300 hasConcept C143998085 @default.
• W4249331300 hasConcept C2776694085 @default.
• W4249331300 hasConcept C2777063308 @default.
• W4249331300 hasConcept C2778239845 @default.
• W4249331300 hasConcept C2780427987 @default.
• W4249331300 hasConcept C2781209748 @default.
• W4249331300 hasConcept C2781451048 @default.
• W4249331300 hasConcept C29730261 @default.
• W4249331300 hasConcept C3019054536 @default.
• W4249331300 hasConcept C71924100 @default.
• W4249331300 hasConcept C90924648 @default.
• W4249331300 hasConcept C98274493 @default.
• W4249331300 hasConceptScore W4249331300C112705442 @default.
• W4249331300 hasConceptScore W4249331300C121608353 @default.
• W4249331300 hasConceptScore W4249331300C126322002 @default.
• W4249331300 hasConceptScore W4249331300C126894567 @default.
• W4249331300 hasConceptScore W4249331300C143998085 @default.
• W4249331300 hasConceptScore W4249331300C2776694085 @default.
• W4249331300 hasConceptScore W4249331300C2777063308 @default.
• W4249331300 hasConceptScore W4249331300C2778239845 @default.
• W4249331300 hasConceptScore W4249331300C2780427987 @default.
• W4249331300 hasConceptScore W4249331300C2781209748 @default.
• W4249331300 hasConceptScore W4249331300C2781451048 @default.
• W4249331300 hasConceptScore W4249331300C29730261 @default.
• W4249331300 hasConceptScore W4249331300C3019054536 @default.
• W4249331300 hasConceptScore W4249331300C71924100 @default.
• W4249331300 hasConceptScore W4249331300C90924648 @default.
• W4249331300 hasConceptScore W4249331300C98274493 @default.
• W4249331300 hasIssue "14_suppl" @default.
• W4249331300 hasLocation W42493313001 @default.
• W4249331300 hasOpenAccess W4249331300 @default.
• W4249331300 hasPrimaryLocation W42493313001 @default.
• W4249331300 hasRelatedWork W1972483602 @default.
• W4249331300 hasRelatedWork W1981260623 @default.
• W4249331300 hasRelatedWork W2015716689 @default.
• W4249331300 hasRelatedWork W2030895179 @default.
• W4249331300 hasRelatedWork W2034009362 @default.
• W4249331300 hasRelatedWork W2089082327 @default.
• W4249331300 hasRelatedWork W2148224723 @default.
• W4249331300 hasRelatedWork W2461409983 @default.
• W4249331300 hasRelatedWork W4246271632 @default.
• W4249331300 hasRelatedWork W4249331300 @default.
• W4249331300 hasVolume "22" @default.
• W4249331300 isParatext "false" @default.
• W4249331300 isRetracted "false" @default.
• W4249331300 workType "article" @default.